2022년 7월 13일 16:45

Extension of the postponement of the settlement of Vifor Pharma tender offer

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Limited (ASX: CSL; USOTC:CSLLY) today announced an update regarding the Vifor Pharma AG acquisition. On January 18, 2022, CSL Behring AG (the Offeror) published the offer prospectus (...

2022년 5월 13일 10:00

Update on the timeline for Vifor Pharma tender offer

Regulatory News: CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022....

2022년 4월 28일 15:30

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

Regulatory News: This press release features multimedia. View the full release here: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing a...

2022년 4월 27일 17:25

94th Vifor Pharma Group Annual General Meeting

Regulatory News: At today’s 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. The Annual General Meeting was again held in accordance with the Ordinance 3 and th...

2022년 4월 4일 14:10

DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve long-term potassium control, reduced the risk of recurrent h...

2022년 3월 28일 15:00

Publication of definitive end result for Vifor Pharma tender offer

CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the definitive notice of the end result of its public tender offer to acquire all publicly held shar...

2022년 3월 23일 16:40

Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent

Regulatory News: This press release features multimedia. View the full release here: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USO...

2022년 3월 8일 17:05

Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the definitive notice of the Interim Res...

2022년 3월 3일 17:30

Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the provisional notice of the interim re...

2022년 2월 28일 15:40

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Regulatory News: This press release features multimedia. View the full release here: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has ...

2022년 2월 3일 09:35

Vifor Pharma appoints two new members to the Executive Committee

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the appointment of acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Dr. Oliver P. Kronenberg as members of the Vifor Pharma E...

2022년 1월 20일 10:00

VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, act...

2021년 12월 21일 17:30

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hype...

2021년 12월 20일 15:40

Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sankyo Group company, today announced that they have reached settlement agreements with Mylan Laboratories Ltd., and Sa...

2021년 12월 16일 15:30

Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization (CD...

2021년 12월 14일 17:05

CSL Limited announces tender offer to acquire Vifor Pharma Ltd

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in iron defic...

2021년 12월 13일 17:31

Vifor Pharma comments on media speculation

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on these discussions...

2021년 12월 13일 14:35

First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease

Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult patients with sickle cell disease. Vamifeport, dev...

2021년 12월 10일 16:25

Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma Executive Committee as of 17 January 2022. Hervé Gisserot, ...

2021년 12월 10일 16:20

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from the exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involv...

2021년 12월 3일 11:50

Vifor Pharma comments on market speculations

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Due to current market speculations, Vifor Pharma Group states the following: Vifor Pharma Group systematically reviews options that can strengthen its market position and/or accelerate th...

2021년 11월 30일 15:36

Vifor Pharma announces changes to the Executive Committee as CFO retires

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021 at his own request. Vifor Pharma is currently in the r...

2021년 11월 26일 15:30

Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis

Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance including the Heart Failure Policy Network, European Kidney Health Alliance, Global Heart Hub and Croí the West of Ireland...

2021년 11월 22일 15:50

Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease pati...

2021년 11월 12일 15:35

VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Tavneos® (avacopan) in combination with a ri...